GlassScriptPhysician profile
Joseph J Gemmete
NPI 1578510517
$14,543.70
in general payments reported to CMS, 2019-2025
7 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Vascular & Interventional Radiology providers received nationally (typical 2025 total: $537).
See the full distribution for Vascular & Interventional Radiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.54 · 2020: $93.35 · 2022: $163 · 2023: $149 · 2024: $2,562 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $14K · Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,800.00 |
| Food and Beverage | $420.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baylis Medical Technologies INC. | $13,800.00 | 2024-2025 | |
| Stryker Corporation | $163.18 | 2022 | |
| Siemens Medical Solutions USA, INC. | $159.89 | 2019-2020 | |
| Vertos Medical, INC. | $148.93 | 2023 | Mild Device Kit |
| Inari Medical, INC. | $144.01 | 2024-2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Penumbra, INC. | $127.69 | 2024 | Indigo System |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$244,917.39 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Gemmete listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.